Pdgfrβ-Cre小鼠的应用: 1. 血管生物学研究: Pdgfrβ-Cre小鼠广泛用于研究血管平滑肌细胞和周细胞在血管发育和功能中的作用。通过在这些细胞中特异性地删除或激活基因,研究人员可以深入了解这些基因在血管形成和维持中的作用。 2. 血管相关疾病研究: Pdgfrβ-Cre小鼠被用于研究与血管平滑肌细胞和周细胞相关的疾病,如...
Reporter lines showed labeling of NG2+, desmin+, PDGFR尾+ perivascular cells in the retina and the brain, indicating successful targeting of pericytes; however, signal from reporter lines was also observed in a small subset of glial cells both in the retina and the brain. We also evaluated ...
Crenolanib(CP-868596;ARO 002)是一种可口服的、有效的、选择性的III型酪氨酸激酶PDGFRα/β、FLT3抑制剂,其IC50值分别是11 nM、3.2 nM和4 nM。Crenolanib在CHO细胞中选择性抑制PDGFRα/β,其Kd值分别为2.1 nM和3.2 nM。 产品性质 英文别名(English Synonym) ...
CP868596 (Crenolanib) is an orally-available, benzimidazole-based inhibitor of PDGFRa and PDGFRb with IC50 values of 0.9 and 1.8 nM, respectively. Fu | CP-868569, CP 868596, CP868569, Crenolanib , 670220-88-9, PDGFR, Kinase
Crenolanib (CP-868596)是一种有效的，选择性的PDGFRα/β抑制剂，K为2.1 nM/3.2 nM，也有效抑制FLT3，对D842V突变型而不是V561D突变型敏感，作用于PDGFR比作用于c-Kit， VEGFR-2， TIE-2， FGFR-2， EGFR， erbB2，和Src选择性高100倍以上。实验操作来自于公开的文献，仅供参考 细胞实验 细胞系...
Crenolanib is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR
Downregulation of the PDGFR signaling pathway on days 7 to 9 with crenolanib significantly increased apoptosis of the neuroblasts that had migrated to the peri-infarct region, increased the number of activated microglia, and decreased the expression of brain-derived neurotrophic factor, neurotrophin-3...
Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncotargets Ther 7, 1761-1768.Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits...
The present invention includes methods for treating a PDGFR伪 mutated proliferative disorder in a subject relapsed/refractory to prior tyrosine kinase inhibitor therapy comprising administering to the subject a therapeutically effective of crenolanib,; ;wherein the subject is relapsed/refractory to prior ...
The present invention includes methods for treating a PDGFR伪 mutated proliferative disorder in a subject relapsed/refractory to prior tyrosine kinase inhibitor therapy comprising administering to the subject a therapeutically effective of crenolanib, wherein the subject is relapsed/refractory to prior ...